LGR5 and neoplasm: This study explored the prognostic utility of measuring mRNA expression levels of three CSC biomarkers, i.e., EpCAM, LGR5 and LGR4, in primary tumors and regional lymph nodes of CC patients and the possible advantage of combining them with the abovementioned markers to further detect different subgroups of tumor cells and/or combinations of tumor cell subgroups and other cell types supporting tumor growth.